Stay updated with breaking news from Biocon Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Slowing global economic conditions are expected to trigger greater utilisation of generic drugs and biosimilars because they offer lower-cost alternatives to expensive branded drugs, she said.
The new proposal is an alteration to the original plan announced on September 2021 where Biocon Biologics had offered approximately 15 per cent stake to Serum at a valuation of USD 4.9 billion
Serum Institute of India, which is the world’s biggest vaccine maker, is set to ramp up its investment in one of Biocon’s subsidiaries to $300 million.
Plenty of stock-specific activity, particularly in some of the railway names, but the sense one gets talking to market players is nobody is making serious money
Biocon Biologics Ltd and Serum Institute of Life Sciences have reached an agreement to withdraw from the original equity structure contemplated under their Strategic Alliance announced in Sep, 2021.